Frank Tang
Morgan Stanley
To start off, for those in the audience that are not familiar with ORIC, could you guys give us an overview of where the company sits today, your lead programs and your priorities now that you crossed into late-stage development?
Jacob Chacko
President, CEO & Director
Sure. Happy to, Frank, and thanks for having us. So ORIC Pharmaceuticals, ORIC stands for Overcoming Resistance in Cancer. In a nutshell, that’s the mission of the company. We are today focused on executing across 2 late-stage development programs. So rinzimetostat, which is a PRC2 inhibitor that’s being developed in prostate cancer in combination with 2 of the big 3 androgen receptor inhibitors in prostate cancer.
That has just started its first Phase III study, a study called Himalayas-1, which is in the castration-resistant prostate cancer setting in patients who are post-abiraterone. I’m sure we’ll talk a lot about that today. And then our second program, enozertinib, which is a brain-penetrant TKI for lung cancer, which is being developed in 2 different populations within the EGFR family of mutations, so EGFR exon 20 and then separately EGFR atypical mutations.
That’s a program that will have a